Literature DB >> 25733512

Impact of β-lactamase inhibition on the activity of ceftaroline against Mycobacterium tuberculosis and Mycobacterium abscessus.

Vincent Dubée1, Daria Soroka2, Mélanie Cortes2, Anne-Laure Lefebvre2, Laurent Gutmann3, Jean-Emmanuel Hugonnet2, Michel Arthur2, Jean-Luc Mainardi4.   

Abstract

The production of β-lactamases Bla(Mab) and BlaC contributes to β-lactam resistance in Mycobacterium abscessus and Mycobacterium tuberculosis, respectively. Ceftaroline was efficiently hydrolyzed by these enzymes. Inhibition of M. tuberculosis BlaC by clavulanate decreased the ceftaroline MIC from ≥ 256 to 16 to 64 μg/ml, but these values are clinically irrelevant. In contrast, the ceftaroline-avibactam combination should be evaluated against M. abscessus since it inhibited growth at lower and potentially achievable drug concentrations.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25733512      PMCID： PMC4394810          DOI： 10.1128/AAC.05080-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  25 in total

1.  Iatrogenic Mycobacterium abscessus infection associated with acupuncture: clinical manifestations and its treatment.

Authors:  Hwa Jung Ryu; Woo Joo Kim; Chil Hwan Oh; Hae Jun Song
Journal:  Int J Dermatol       Date:  2005-10       Impact factor: 2.736

2.  Rapid, low-technology MIC determination with clinical Mycobacterium tuberculosis isolates by using the microplate Alamar Blue assay.

Authors:  S G Franzblau; R S Witzig; J C McLaughlin; P Torres; G Madico; A Hernandez; M T Degnan; M B Cook; V K Quenzer; R M Ferguson; R H Gilman
Journal:  J Clin Microbiol       Date:  1998-02       Impact factor: 5.948

3.  β-Lactamase inhibition by avibactam in Mycobacterium abscessus.

Authors:  Vincent Dubée; Audrey Bernut; Mélanie Cortes; Tiffany Lesne; Delphine Dorchene; Anne-Laure Lefebvre; Jean-Emmanuel Hugonnet; Laurent Gutmann; Jean-Luc Mainardi; Jean-Louis Herrmann; Jean-Louis Gaillard; Laurent Kremer; Michel Arthur
Journal:  J Antimicrob Chemother       Date:  2014-12-18       Impact factor: 5.790

4.  Genetic analysis of the beta-lactamases of Mycobacterium tuberculosis and Mycobacterium smegmatis and susceptibility to beta-lactam antibiotics.

Authors:  Anthony R Flores; Linda M Parsons; Martin S Pavelka
Journal:  Microbiology       Date:  2005-02       Impact factor: 2.777

Review 5.  Nontuberculous mycobacteria: the changing epidemiology and treatment challenges in cystic fibrosis.

Authors:  Janice M Leung; Kenneth N Olivier
Journal:  Curr Opin Pulm Med       Date:  2013-11       Impact factor: 3.155

6.  In vitro activity of amoxicillin in combination with clavulanic acid against Mycobacterium tuberculosis.

Authors:  M H Cynamon; G S Palmer
Journal:  Antimicrob Agents Chemother       Date:  1983-09       Impact factor: 5.191

7.  Comparing Mycobacterium massiliense and Mycobacterium abscessus lung infections in cystic fibrosis patients.

Authors:  Anne-Laure Roux; Emilie Catherinot; Nathalie Soismier; Beate Heym; Gil Bellis; Lydie Lemonnier; Raphaël Chiron; Brigitte Fauroux; Muriel Le Bourgeois; Anne Munck; Isabelle Pin; Isabelle Sermet; Cristina Gutierrez; Nicolas Véziris; Vincent Jarlier; Emmanuelle Cambau; Jean-Louis Herrmann; Didier Guillemot; Jean-Louis Gaillard
Journal:  J Cyst Fibros       Date:  2014-07-30       Impact factor: 5.482

8.  Permeability barrier to hydrophilic solutes in Mycobacterium chelonei.

Authors:  V Jarlier; H Nikaido
Journal:  J Bacteriol       Date:  1990-03       Impact factor: 3.490

9.  A shorter treatment duration may be sufficient for patients with Mycobacterium massiliense lung disease than with Mycobacterium abscessus lung disease.

Authors:  Jiwon Lyu; Bum-Joon Kim; Byeong-Joon Kim; Jin Woo Song; Chang-Min Choi; Yeon-Mok Oh; Sang-Do Lee; Woo Sung Kim; Dong Soon Kim; Tae Sun Shim
Journal:  Respir Med       Date:  2014-09-16       Impact factor: 3.415

10.  Characterization of broad-spectrum Mycobacterium abscessus class A β-lactamase.

Authors:  Daria Soroka; Vincent Dubée; Olivia Soulier-Escrihuela; Guillaume Cuinet; Jean-Emmanuel Hugonnet; Laurent Gutmann; Jean-Luc Mainardi; Michel Arthur
Journal:  J Antimicrob Chemother       Date:  2013-10-16       Impact factor: 5.790
View more
  16 in total

1.  Select β-Lactam Combinations Exhibit Synergy against Mycobacterium abscessus In Vitro.

Authors:  Elizabeth Story-Roller; Emily C Maggioncalda; Gyanu Lamichhane
Journal:  Antimicrob Agents Chemother       Date:  2019-03-27       Impact factor: 5.191

2.  Inhibition of the β-Lactamase BlaMab by Avibactam Improves the In Vitro and In Vivo Efficacy of Imipenem against Mycobacterium abscessus.

Authors:  Anne-Laure Lefebvre; Vincent Le Moigne; Audrey Bernut; Carole Veckerlé; Fabrice Compain; Jean-Louis Herrmann; Laurent Kremer; Michel Arthur; Jean-Luc Mainardi
Journal:  Antimicrob Agents Chemother       Date:  2017-03-24       Impact factor: 5.191

3.  New β-Lactamase Inhibitors Nacubactam and Zidebactam Improve the In Vitro Activity of β-Lactam Antibiotics against Mycobacterium abscessus Complex Clinical Isolates.

Authors:  Amit Kaushik; Nicole C Ammerman; Nicole M Parrish; Eric L Nuermberger
Journal:  Antimicrob Agents Chemother       Date:  2019-08-23       Impact factor: 5.191

Review 4.  Strategic Moves of "Superbugs" Against Available Chemical Scaffolds: Signaling, Regulation, and Challenges.

Authors:  Bikash Baral; M R Mozafari
Journal:  ACS Pharmacol Transl Sci       Date:  2020-04-13

5.  Efficacy of Bedaquiline, Alone or in Combination with Imipenem, against Mycobacterium abscessus in C3HeB/FeJ Mice.

Authors:  Vincent Le Moigne; Clément Raynaud; Flavie Moreau; Christian Dupont; Jérôme Nigou; Olivier Neyrolles; Laurent Kremer; Jean-Louis Herrmann
Journal:  Antimicrob Agents Chemother       Date:  2020-05-21       Impact factor: 5.191

6.  Molecular Mechanisms of Intrinsic Streptomycin Resistance in Mycobacterium abscessus.

Authors:  Michael Dal Molin; Myriam Gut; Anna Rominski; Klara Haldimann; Katja Becker; Peter Sander
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

7.  Insights into the l,d-Transpeptidases and d,d-Carboxypeptidase of Mycobacterium abscessus: Ceftaroline, Imipenem, and Novel Diazabicyclooctane Inhibitors.

Authors:  Khalid M Dousa; Sebastian G Kurz; Magdalena A Taracila; Tracey Bonfield; Christopher R Bethel; Melissa D Barnes; Suresh Selvaraju; Ayman M Abdelhamed; Barry N Kreiswirth; W Henry Boom; Shannon H Kasperbauer; Charles L Daley; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2020-07-22       Impact factor: 5.191

Review 8.  An Update in Antimicrobial Therapies and Infection Prevention in Pediatric Lung Transplant Recipients.

Authors:  O C Smibert; M A Paraskeva; G Westall; Greg Snell
Journal:  Paediatr Drugs       Date:  2018-12       Impact factor: 3.022

Review 9.  Pipeline of anti-Mycobacterium abscessus small molecules: Repurposable drugs and promising novel chemical entities.

Authors:  Anna Egorova; Mary Jackson; Victor Gavrilyuk; Vadim Makarov
Journal:  Med Res Rev       Date:  2021-03-01       Impact factor: 12.388

10.  "One-Two Punch": Synergistic ß-Lactam Combinations for Mycobacterium abscessus and Target Redundancy in the Inhibition of Peptidoglycan Synthesis Enzymes.

Authors:  David C Nguyen; Khalid M Dousa; Sebastian G Kurz; Sheldon T Brown; George Drusano; Steven M Holland; Barry N Kreiswirth; W Henry Boom; Charles L Daley; Robert A Bonomo
Journal:  Clin Infect Dis       Date:  2021-10-20       Impact factor: 20.999
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.